Pepvise
Compound profile· Compounds

DSIP peptide, what the evidence shows

By The PepVise Editorial Team · Reviewed July 2, 2026 · 13 min read

Evidence Ledger for DSIP (delta sleep-inducing peptide): a neuropeptide isolated from rabbit brain in 1977 and marketed online for sleep, whose human sleep data are old, small, and inconsistent, with no FDA approval.

We describe what has been measured, by whom, at what scale, with what effect size, and with what caveats. Hedging, here, is honesty.
The PepVise Editorial Teamfrom the house style guide
Editorial reference
Primary literature

PubMed saved search, 'delta sleep-inducing peptide'

DSIP is a compound where the search itself is the most honest starting point, because it shows how much of the human work dates to the 1980s, how small it is, and how the core sleep findings were themselves inconsistent. A saved search makes the age and thinness of the evidence visible directly, more honestly than any summary, including ours.

Reference reading

The texts we read alongside the papers.

  1. 01
    Primary literature

    PubMed saved search, 'delta sleep-inducing peptide'

    A PubMed search surfaces the defining pattern: much of the human literature on DSIP was published in the 1980s, with small samples and inconsistent sleep outcomes. It is the fastest way to see that the modern marketing as a sleep aid runs well ahead of what those early, unreplicated studies actually measured.

  2. 02
    Reference text

    Principles and Practice of Sleep Medicine (Kryger, Roth, Dement)

    The standard sleep-medicine reference sets the bar any sleep claim must clear: validated sleep architecture, polysomnography, and clinical endpoints. It does not treat DSIP as an established therapy, and that omission is itself informative when reading the online claims.

  3. 03
    Popular-science background

    Why We Sleep, Matthew Walker, PhD

    Walker's framework for what genuine, measurable sleep looks like, and how easily sleep claims outrun the data, is exactly the discipline DSIP requires. The book does not cover DSIP directly; the reasoning framework is the point.

Methodology

How we read the literature

Evidence tier
We grade the literature on four tiers, High (replicated RCTs or meta-analyses), Moderate (multiple trials with mixed findings), Low (a single pilot or case series), and Anecdotal (preclinical only, no human data). The tier appears on every compound profile beside the claim it supports.
Trial stage
Where a compound sits in the human development pipeline is recorded as Preclinical, Phase 1, Phase 2, or Phase 3+. We pull the current stage from ClinicalTrials.gov and the EU Clinical Trials Register on access date and re-verify quarterly.
Regulatory status
We state the FDA posture plainly, approved for indication X, or labeled for research use only, or removed from the 503A list, or investigational under a specific IND. Regulatory status changes; every post carries a review date.
Where we're uncertain
Every compound profile closes with a named uncertainty section, the question we can't answer from the current literature, the trial we'd want to see, the effect size we'd treat as a real signal. Uncertainty is not a failure mode here; it's load-bearing.
Frequently asked

The questions readers actually bring us.

Is DSIP FDA-approved?
No. DSIP has no FDA-approved indication and is not registered as a drug. It circulates as a research chemical labeled for non-human use. Despite the name, it is not an approved sleep aid.
Does DSIP actually improve sleep?
The human evidence is old, small, and inconsistent. The name comes from a 1977 observation in rabbits, and the few human studies in the 1980s produced mixed results. There are no modern, well-controlled trials using validated sleep architecture that establish a reliable sleep-promoting effect.
What does DSIP stand for?
Delta sleep-inducing peptide. It was named for the delta-wave sleep activity associated with the blood fraction it was isolated from in sleeping rabbits in 1977. The name reflects an early hypothesis about its function rather than a confirmed, reproducible clinical effect.
How does DSIP work?
Its physiological mechanism is not well established. It is an endogenous nine-amino-acid neuropeptide that has been studied for possible roles in sleep, stress, and thermoregulation, but no single mechanism is confirmed, and the breadth of proposed effects is one reason its biology remains murky.
Why does PepVise not give a DSIP dose?
Because we describe the literature and do not recommend administration. The doses repeated online come from forums, not from replicated dose-finding trials, and the human data are too thin to define a validated dose in the first place. We explain how these research chemicals are regulated separately.
What would change our reading

A Phase 2 randomized trial with blinded outcome assessment would change the reading. A new independent replication outside the currently dominant research group would change the reading. A regulatory action, approval, restriction, or a class warning, would change the reading. When any of those lands, we update this profile within a week and mark what changed.

The masthead

About The Pepvise Editorial Team

The Pepvise Editorial Team is a small group of researchers and science writers reading the peer-reviewed peptide literature and translating it into calm, cited analysis. We do not sell peptides, recommend peptides, or tell readers what to administer. We describe what has been measured, by whom, at what scale, with what effect size.

Compound reviews are signed off by Dr. Priya Narang, MD, MPH (endocrinologist) and Dr. Marcus Haley, PharmD, BCPS (board-certified clinical pharmacist). Both hold verifiable state-board licenses and have signed editorial-independence letters with us. See the full editorial board →

Further reading

Adjacent in the literature.

Compounds · Compound profile

BPC-157, What the Evidence Shows

Evidence Ledger for BPC-157: 50+ preclinical studies, 1 human pilot (Chang 2014, n=12), 1 active Phase trial, FDA removed from 503A list in 2023.

16 min readCompounds · Compound profile

TB-500, The Field Guide

TB-500 vs Thymosin Beta-4 (same compound), mechanism, the preclinical tendon and recovery literature, and where the human data is thin.

14 min readCompounds · Compound profile

GHK-Cu, Evidence and Hype

Copper peptide signaling, the topical RCT evidence for hair and skin, and the gap between topical and injectable claims.

13 min read

Get the 2026 Peptide Evidence Ledger.

A 12-page PDF summary of where 10 major compounds sit, Preclinical / Human pilot / Phase trial / FDA status. Updated quarterly. Free.

By subscribing, you agree to our Privacy Policy. One calm, cited email a week. Unsubscribe anytime.